As we now know from our experience with the COVID-19 pandemic, the microbes responsible for some infections can rapidly mutate into variants that evade detection and treatment. But now, researchers reporting in ACS Infectious Diseases have developed a procedure that could help researchers catch up to these sneaky pathogens. Their “AutoPLP” technique designs nucleic acid probes to detect new variants quickly, accurately and easily.
Many diagnostics, such as those based on the polymerase chain reaction (PCR) detect pathogens by analyzing genetic material. Rolling circle amplification (RCA) works in a similar way, though an advantage is that it doesn’t involve the complex temperature cycling that PCR does. Both techniques require nucleic acid probes with sequences matching those of the target pathogen in specific locations, but RCA uses highly specific “padlock probes” (PLPs). As a pathogen mutates, its genetic sequence changes as well, and researchers have to keep redesigning their probes. So, Sowmya Krishnan, Ruben Soares, M. Michael Gromiha and Narayanan Madaboosi wanted to create a tool that could not only design these PLPs automatically, but also, for the first time, systematically consider all the necessary technical parameters at once to make the entire process easier and more robust.
Their tool, a computer program called “AutoPLP,” was named after the PLPs it designs. The program can take the genome sequences of similar pathogens as input and run a series of analyses and database searches, outputting a set of customized PLP sequences. The team used the program to design probes against the rabies virus, a virus transmitted between animals and people, and Mycobacterium tuberculosis, the bacterium responsible for tuberculosis, and compared them to previously reported ones. For the rabies virus, AutoPLP targeted three genes, yielding probes with a higher and narrower range of melting temperatures than those in the literature. For M. tuberculosis, they designed a total of 13 probes specifically targeting two genes responsible for drug-resistant strains with the program. The researchers say that this tool could help hasten the discovery of new pathogen variants, helping combat them rapidly and effectively via precise molecular diagnostics.
The authors acknowledge funding from the 2020-2021 Ramalingaswami Re-Entry Fellowship from the Department of Biotechnology, Government of India.
The paper’s abstract will be available on Feb. 15 at 8 a.m. Eastern time here: https://pubs.acs.org/doi/abs/10.1021/acsinfecdis.2c00436
For more of the latest research news, register for our upcoming meeting, ACS Spring 2023. Journalists and public information officers are encouraged to apply for complimentary press registration by completing this form.
The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS’ mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and all its people. The Society is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACS’ main offices are in Washington, D.C., and Columbus, Ohio.